Abstract
Background: In LIBERTY AD PEDS phase 3 trial (NCT03345914) in children with severe AD, dupilumab significantly improved AD signs and symptoms. We assess time to onset of improvement in pruritus in a subset of children treated with FDA-approved doses of dupilumab.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
